Saskia A C Luelmo
Overview
Explore the profile of Saskia A C Luelmo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schaeffers A, van Neerven C, van Balen D, Crul M, Slingerland M, Luelmo S, et al.
Br J Clin Pharmacol
. 2025 Feb;
PMID: 39989079
Aims: The aim of this study was to determine if head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin chemoradiotherapy and short hydration (SH) experience less dose-limiting toxicity...
2.
Kleiburg F, de Geus-Oei L, Spijkerman R, Noortman W, van Velden F, Manohar S, et al.
Eur Radiol
. 2025 Jan;
PMID: 39843627
Objective: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with varying survival outcomes. This study investigated whether baseline PSMA PET/CT parameters are associated with survival and treatment response. Methods:...
3.
van Olden M, de Jong-Hesse Y, Vollebregt T, de Groot S, Luelmo S, Marinkovic M
Case Rep Ophthalmol
. 2024 Mar;
15(1):184-188.
PMID: 38456120
Introduction: In this paper, we report a case of visual impairment during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Methods: Retrospective chart review was used. Case...
4.
Mackay T, Latenstein A, Augustinus S, van der Geest L, Bogte A, Bonsing B, et al.
JAMA Surg
. 2024 Feb;
159(4):429-437.
PMID: 38353966
Importance: Implementation of new cancer treatment strategies as recommended by evidence-based guidelines is often slow and suboptimal. Objective: To improve the implementation of guideline-based best practices in the Netherlands in...
5.
Augustinus S, Broekman T, Creemers G, Daamen L, van Dieren S, de Groot J, et al.
Acta Oncol
. 2023 Oct;
62(12):1973-1978.
PMID: 37897803
No abstract available.
6.
van t Land F, Aziz M, Michiels N, Mieog J, Bonsing B, Luelmo S, et al.
Ann Surg
. 2023 Apr;
278(6):1018-1023.
PMID: 37010512
Background And Objectives: A high systemic immune-inflammation index (SIII) at diagnosis of various cancers, including pancreatic cancer, is associated with poor prognosis. The impact of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and...
7.
Klatte D, Boekestijn B, Onnekink A, Dekker F, van der Geest L, Wasser M, et al.
Gastroenterology
. 2023 Mar;
164(7):1223-1231.e4.
PMID: 36889551
Background & Aims: Recent pancreatic cancer surveillance programs of high-risk individuals have reported improved outcomes. This study assessed to what extent outcomes of pancreatic ductal adenocarcinoma (PDAC) in patients with...
8.
van der Sijde F, Dik W, Mustafa D, Vietsch E, Besselink M, Debets R, et al.
Front Immunol
. 2022 Sep;
13:898498.
PMID: 36091056
Background: Biomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of...
9.
Klatte D, Boekestijn B, Wasser M, Feshtali Shahbazi S, Ibrahim I, Mieog J, et al.
J Clin Oncol
. 2022 Jun;
40(28):3267-3277.
PMID: 35658523
Purpose: Pancreatic cancer surveillance in high-risk individuals may lead to detection of pancreatic ductal adenocarcinoma (PDAC) at an earlier stage and with improved survival. This study evaluated the yield and...
10.
Versteijne E, van Dam J, Suker M, Janssen Q, Groothuis K, Akkermans-Vogelaar J, et al.
J Clin Oncol
. 2022 Jan;
40(11):1220-1230.
PMID: 35084987
Purpose: The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS)...